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 ABSTRACT 
 Older patients, suff ering from numerous diseases and taking multiple medications are the rule rather than the exception in primary 
care. A manifold of medical conditions are often associated with poor outcomes, and their multiple medications raise additional risks 
of polypharmacy. Such patients account for most healthcare expenditures. Eff ective approaches are needed to manage such complex 
patients in primary care. This paper describes the results of a scoping exercise, including a two-day workshop with 17 professionals 
from six countries, experienced in general practice and primary care research as well as epidemiology, clinical pharmacology, gerontol-
ogy and methodology. This was followed by a consensus process investigating the challenges and core questions for multimorbidity 
research in primary care from a clinical perspective and presents examples of the best research practice. Current approaches in meas-
uring and clustering multimorbidity inform policy-makers and researchers, but research is needed to provide support in clinical decision 
making. Multimorbidity presents a complexity of conditions leading to individual patient ’ s needs and demanding complex processes 
in clinical decision making. The identifi cation of patterns presupposes the development of strategies on how to manage multimorbid-
ity and polypharmacy. Interventions have to be complex and multifaceted, and their evaluation poses numerous methodological 
challenges in study design, outcome measurement and analysis. Overall, it can be seen that complexity is a main underlying theme. 
Moreover, fl exible study designs, outcome parameters and evaluation strategies are needed to account for this complexity. 
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 KEY MESSAGE: 
•  Multimorbidity is resulting in complex (health) care situations, while evidence-based clinical decision support for care for 
patients with multimorbidity is lacking. 
•  Both interventions to handle patients with multimorbidity and study designs evaluating these interventions are bound to 
be complex, and hence need to be fl exible. 
•  Hard end points such as hospitalization and mortality are common; patient-centred and holistic measures — such as the assess-
ment of health related quality of life — are essential, but users should be aware of the underlying multidimensional constructs. 
 INTRODUCTION 
 Mr Curran is a single farmer aged 62 years, who has been 
living by himself, in a rural community in western Ireland. 
After a lifetime of herding sheep and cattle in rough 
terrain, he developed osteoarthritis of the knees. This 
condition limits his mobility. The resulting lack of activity 
led to signifi cant weight gain. The increase in weight 
together with a 40-year history of smoking contributed 
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to the onset of chronic obstructive pulmonary disease 
(COPD), type 2 diabetes, atrial fi brillation and hyper-
tension. These diseases were only discovered when 
Mr Curran suff ered an acute cardio-embolic stroke 
(residual dysarthria and hemiparesis) and associated 
chronic kidney disease. Other diagnoses detected during 
his hospitalization include hyperlipidaemia, hyperuricae-
mia and fi nally benign prostatic hyperplasia (BPH). 
 In a relatively short time, Mr Curran has evolved 
from a fi ercely independent man to a person struggling 
to navigate his way through a healthcare system that 
appears to him to be increasingly complex and frag-
mented. His numerous prescriptions now include 13 
medications (see Table 1); he has had 42 primary care 
consultations over the past year with nurses, his family 
doctor, speech therapist, occupational therapist, and 
physiotherapist. In addition, Mr Curran has to be present 
regularly at three diff erent outpatient clinics in a hospital 
centre that is a 1.5-h drive away by car but he is unable 
to drive anymore. Furthermore, he has been admitted 
twice to hospital in the last year.  ‘ Frustrated, ’  ‘ worried, ’ 
 ‘ confused ’ are the words Mr Curran uses to describe 
himself in his journey through healthcare. 
 Mr Curran ’ details have been altered to protect his 
anonymity, but he constitutes a typical case of multi-
morbidity based on a real patient. Patients like him are 
the rule rather than the exception in primary care (1 – 3). 
Multiple health conditions often result in the prescribing 
of complex regimes including multiple drugs with the 
potential for drug-drug and drug-disease interactions. 
Further risks associated with multimorbidity and polyp-
harmacy are over or under treatment, as well as decreased 
(medication) adherence (4 – 7). Evidence-based clinical 
decision support for such patients is sparse (8), and the 
mere application of current disease-oriented clinical prac-
tice guidelines may actually have harmful consequences 
(9,10). In addition, multiple chronic medical conditions 
are associated with poor outcomes: decreased quality of 
life, psychological distress, longer hospital stays, more 
postoperative complications and higher mortality (11 – 14). 
Healthcare costs increase exponentially with the number 
of chronic diseases (15,16), which altogether constitutes 
complex problems that clinicians and researchers are 
attempting to solve. 
 These complex problems pose several challenges 
(17,18). Eff ective approaches to managing these patients 
in primary health care are needed and have to be tai-
lored to diff erent health care systems (19). Furthermore, 
selecting adequate research methodologies for studying 
diagnosis and treatment of such complex patients is not 
easy (20). 
 THE SCOPING APPROACH 
 An International Workshop on Methodological Research 
Strategies in Multimorbidity was held in Frankfurt/Main 
(Germany) on 4 – 5 February 2011. Seventeen partici-
pants from six countries (Canada, Germany, Ireland, the 
Netherlands, Spain and the UK) represented general 
practice and primary care research including epidemiol-
ogy ( n    12), clinical pharmacology ( n    1), gerontology 
( n    2) and methodology ( n    2). A scoping exercise was 
used to examine the extent, range and nature of relevant 
research activities regarding multimorbidity research in 
primary care. Diff erent defi nitions for the term  ‘ scoping ’ 
exist, but it is an accepted method to  ‘ map ’ relevant 
information in interest. Advantages of scoping are that 
topics can be dealt with within a relatively broad range, 
and concepts underpinning a research area can be 
mapped quickly (21). Scoping is especially useful when 
it is diffi  cult to visualize the range of available material. 
 Fifteen experts presented experiences from diff er-
ent fi eld studies and their theoretical and epidemiolog-
ical backgrounds (for full programme of the expert 
meeting see: http://www.allgemeinmedizin.uni-frank-
furt.de/forschung2/int_workshop.html). Group discus-
sions were audio-taped and later summarized and 
reframed by three of the speakers (CM, MvdA, MB). 
Thirteen of the participants (all authors) re-evaluated 
the results and conducted an iterative process of explo-
ration including a narrative literature review to consider 
the current state of understanding in multimorbidity 
research. We used a case example to elucidate further 
the key issues of the workshop. This paper presents the 
participants ’ consensus, after the expert meeting, anal-
ysis of the audio tapes, additional narrative review and 
written consensus rounds. 
 Our scoping exercise resulted in three main research 
areas illustrated by current research projects and elabo-
rated on our patient, Mr Curran. The fi rst area of focus 
is the various operationalizations of multimorbidity 
concepts and their consequences on measurement and 
 Table 1. Medication regimen of Mr Curran. 
Active pharmaceutical 
ingredient (API) Strength Dosage
Enalapril 20 mg od
Furosemide 40 mg od
Amlodipine 5 mg od
Bisoprolol 5 mg od
Warfarin acc. INR
Amiodarone 200 mg bid
Glimepiride 3 mg od
Allopurinol 300 mg od
Budesonide/Formoterol 160  μ g/4.5  μ g bid
Salbutamol 100 – 200 mcg pa prn
Simvastatin 10 mg od
Tamsulosin 0.4 mg od
Potassium supplementation 40 mval/mEq/mmol od
 Bid, bis in die (twice daily); od, omne in die (once daily); prn, pro re 
nata (as needed); INR, International Normalized Ratio; pa, per 
administration. 
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clustering of multimorbidity. The second area involves 
the description of possible strategies on how to manage 
multimorbidity and polypharmacy in ongoing interven-
tion studies. These provide examples to discuss method-
ological challenges in the third part. 
 Classifi cations and patterns 
 Systematic reviews showed that a wide variety of meth-
ods has been used in studies on the prevalence and pat-
terns of multimorbidity revealing a great variation in 
estimates, making direct comparisons meaningless 
(22,23). As a result, signifi cant challenges exist in the def-
inition, classifi cation and measurement of multimorbidity. 
Measures to quantify multimorbidity vary from a simple 
count of the number of diseases or clusters to calculating 
disease scores, such as the Charlson Index and the 
Cumulative Illness Rating Scale, which both assess the 
presence and weight for the severity of conditions (24,25). 
If morbidity data are not available, classes of drug pres-
criptions from routine dispensing data are sometimes used 
as a proxy for the occurrence of chronic diseases — e.g. 
CDS: Chronic Disease Score (26). Specifi c populations and 
contexts require further revisions and adaptations such as 
the development of the medication based CDS (med-CDS) 
adapted for Germany. The med-CDS aims at assessing mul-
timorbidity in elderly patients to predict health-related 
outcomes (i.e. mortality, hospitalization) and at comparing 
patient populations by medication data (27). 
 The above-mentioned measures are used for research 
purposes or to inform policy-makers, but provide little or 
no support to clinical decision making in daily general 
practice. Clinicians caring for older patients with multi-
morbidity such as Mr Curran, tend to group conditions 
that are either causally related or intertwined complica-
tions. Concepts of  ‘ disease-related ’ or  ‘ causal ’ multi-
morbidity refl ect the needs in clinical decision making 
(28 – 30); a recent approach is the example of  ‘ cardio-
vascular multimorbidity. ’ This is used to describe the 
often related morbidities of cardiovascular disease 
(CVD), diabetes mellitus and chronic kidney disease 
(CKD) (see Box 1). Apart from causally related disease 
clusters, patients frequently present combinations of 
diseases for which the GP has no reasonable explanation 
of a pathophysiologic relationship, also called  ‘ general 
susceptibility ’ (29). 
 Interventions 
 Multimorbidity. GPs need specifi c strategies to handle 
patients with multimorbidity. Some of them have been 
studied, to address multimorbidity in general practice 
(38). The fi rst type of strategy is based on the implemen-
tation of single interventions that may be benefi cial for 
many medical conditions, such as the prescription of 
physical exercise (39 – 42) or more complex psychosocial 
interventions (43). Other strategies have focussed on 
specifi c clusters of conditions that may benefi t from con-
cordant management, such as cardiovascular risk man-
agement (44,45). In an attempt to maximize care for 
more complex patients, other approaches are based on 
diff erent models of structured healthcare, for instance, 
the Chronic Care Model (46,47). All these kinds of strat-
egies rely on the assumption that one single interven-
tion, as complex as it may be, would operate on a 
common pathway. For many patients, however, this 
intervention may not be feasible, and a patient-centred 
prioritization of competing needs might actually be one 
of the key issues (48). In Box 2, we provide examples of 
ongoing interventions using Mr Curran ’ s case. 
 Polypharmacy. Polypharmacy is one of most frequent 
consequences of multimorbidity, resulting in serious 
problems. Studies have shown that about 6.5% of all 
hospital admissions are caused by adverse drug reac-
tions (50 – 52), and between 30% and 70% of these 
admissions are seen as preventable (53,54). Rational 
prescribing for patients with multimorbidity relies on a 
patient-centred, instead of a disease-oriented approach 
with clear therapeutic objectives avoiding inappropriate 
medications and underprescribing, as well as the priori-
tization of available therapies (55 – 58). However, imple-
mentation in daily routine is diffi  cult as the translation 
from study conclusions to practical guidance is lacking. 
Another issue is the often inadequate communication 
with patients (59,60). Interventions to address these 
 The classifi cation of  ‘ causal ’ multimorbidity has led to the development of the term  ‘ cardiovascular multimorbidity ’ to describe coexisting 
CVD, diabetes and chronic kidney disease (CKD) (14,31). The rationale for this classifi cation is based on the shared pathophysiologic back-
ground, common interventions, and congruence with daily clinical experience. The risk of developing an additional disease from the spectrum 
of cardiovascular morbidity is often increased (e.g. the risk of a cardiovascular event is increased in patients with diabetes or CKD). In patients 
with established CVD, diabetes is associated with a signifi cantly increased risk of cardiovascular mortality and morbidity as is CKD (32 – 36). 
The level of cardiovascular multimorbidity has been an independent predictor of prognosis for patients with established CVD; in such patients 
the presence of CKD carries a mortality risk similar to that of diabetes (14). Therefore, patients with cardiovascular multimorbidity do not 
simply have an accumulation of conditions but rather a complex interplay of risk factors that accelerate specifi c outcomes of cardiovascular 
events, or death. Mr Curran ’ s hypertension and atrial fi brillation put him at a high risk of developing chronic heart failure (CHF), which may 
have a worse prognosis because of his diabetes, CKD, and other comorbidities (37). Alternatively, a treatment with ACE inhibitors is eff ective 
in hypertension, to reduce the risk of developing CHF in diabetics and slow the progression of a diabetic CKD in a synergistic manner (37). 
 Box 1. Cardiovascular multimorbidity. 
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 PR1MaC, a multifaceted intervention integrating chronic disease rehabilitation services (lifestyle intervention, self-management training, 
and motivational interviewing by multiple professionals) in primary care practices in Canada (NCT01319656). 
 After a consultation during which Mr Curran and his general practitioner (GP) explored the possible link between lifestyles and health 
status, he was referred (including the patient ’ s medical history) to the PR1MaC team so that he could receive support in his own 
environment. Soon thereafter, Mr Curran meets with the PR1MaC nurse at his usual clinic, for a one-hour discussion about how he is 
coping daily with his medical conditions. They discuss how to integrate the required specifi c actions into Mr Curran ’ s daily habits and how 
to overcome the barriers to self-care he is experiencing. Mr Curran is asked to record his symptoms before the next medical visit, so that 
he can discuss these with his GP and obtain specifi c advice. Before agreeing to meet again for a 30-min follow-up visit, Mr Curran accepts 
the nurse ’ s off er to meet a dietician and a physical activity therapist in the upcoming weeks to discuss a suitable exercise regimen adapted 
to his condition. 
 PraCMan,  ‘ primary care practice-based care management for chronically ill patients ’ (ISRCTN56104508) (49): a complex, multifaceted 
intervention on multimorbidity to reduce the likelihood of (re-)hospitalization in Germany. 
 Mr Curran clearly has an increased risk of future hospitalizations because of the complexity and instability of his health status; he 
was already admitted to the hospital twice during the last year. Mr Curran is identifi ed through the family practice based on his 
multimorbidity and his history of (avoidable) hospitalizations and receives a comprehensive assessment of his medical and non-medical 
care needs and resources. He is subsequently monitored by a trained healthcare assistant (e.g. by telephone calls based on a 
structured checklist). The frequency of these calls depends on his needs, and will be increased, for instance if his health status 
becomes unstable, so that any symptom deteriorations can be detected early allowing timely intervention and prevention of 
hospitalization. 
 SMOOTH-Turn sepsis to life!  ‘ Sepsis survivors monitoring and coordination in outpatient health care, ’ (ISRCTN61744782): a transitional 
collaborative care programme to support clinical complex patients after severe sepsis in Germany. 
 Having survived a sepsis — due to a pneumonia exacerbating the COPD and requiring an artifi cial respirator — Mr Curran is followed 
actively and in a structured way for a year. His GP has obtained structured information from the intensive care unit in accordance with a 
discharge management scheme. Mr Curran and his GP have received evidence-based interactive training on sepsis sequels and self-
management by a liaison physician and a nurse case manager. The case manager is monitoring Mr Curran by telephone to track his clinical 
and psychosocial situation. Liaison physicians provide clinical support to the GP. 
 Box 2. Interventions addressing multimorbidity. 
issues frequently consist of several components, such as 
PIL and PRIMUM (see Box 3), and provide examples for 
discussing methodological challenges. 
 Methodological challenges 
 As exemplifi ed in Boxes 2 and 3, interventions on 
multimorbidity and polypharmacy are multifaceted, 
frequently with interacting components, often directed 
at the organization level while measuring outcomes at 
patient-level, i.e. interventions are complex (61). Addi-
tionally, the study population of patients with multi-
morbidity is often complex, but at least heterogeneous. 
Attempting to evaluate those interventions in these 
patients ’ points towards several methodological chal-
lenges highlighted in the following: 
 Study design. The best type of evidence for the eff ec-
tiveness of an intervention is information obtained 
from a large, well-conducted randomized controlled 
trial (RCT). However, the evaluation of complex inter-
ventions, such as those used to address multimorbidity 
and polypharmacy (see Boxes 2 and 3) pose specifi c 
challenges (61). 
 The multi-component nature of these interventions 
is part of the design as it aims to be: fl exible but at the 
same time reproducible. Flexibility is needed to adapt to 
diff erent requirements of the intervention and study 
protocol, and conditions of the deliverer (e.g. general 
practitioner) (see Figure 1). However, the intervention 
needs to be reproducible, because otherwise the evalu-
ation or implementation of this intervention would be 
impossible (62). 
 This tension means that protocols defi ning the 
required aspects (such as content and timing) of each 
component must be clearly specifi ed not only for the 
intervention itself, but also for the control used in the 
evaluation (62). These protocols should be the basis of 
the delivery of the intervention during the evaluation 
and the implementation phases and should determine 
how fl exible each component can be. 
 Finally, measuring the fi delity in delivery of the pro-
tocol is crucial to determine what is actually being eval-
uated. To establish the feasibility of evaluating this 
intervention in a trial, evidence of fi delity should be col-
lected during the pilot phase together with recruitment, 
compliance, and attrition rates (63). 
 Outcome measurement. The choice of outcome 
measures depends on the relevance for patients and 
appropriateness to detect pre- and post-intervention dif-
ferences. Furthermore, it depends on the main research 
question, feasibility, and methodological issues, such as 
study design and setting. Mortality, hospitalizations and 
disease-specifi c outcomes — typical endpoints in clinical 
trials to prove for instance the effi  cacy of drugs — are less 
frequently used as primary outcomes in interventions on 
polypharmacy: these endpoints are often not feasible 
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 Apart from the previously mentioned patient-re-
ported outcomes, there are other ways to establish study 
eff ects. In the case of complex interventions regarding 
polypharmacy in primary care, the Medication Appropri-
ateness Index (MAI) is a useful outcome measure (see 
Box 5). 
 Process evaluation. The choice of (clinically) relevant 
outcome parameters is challenging, but so is their anal-
ysis. The evaluation of complex interventions requires 
not only an answer to the pragmatic question of 
whether an intervention works, but also an answer to 
the explanatory question of how it works (61). The 
assessment of potential moderators and mediators may 
be helpful to explain intervention eff ects or to investi-
gate the reasons for an intervention ’ s failure to yield 
the expected outcome. Moderators are baseline vari-
ables that only modify the relationship between an 
intervention and its outcome (82,83). In contrast, medi-
ators occur on the causal pathway between an inter-
vention and its outcome (see Figure 2). Evaluation of 
such process variables can help improve interventions. 
For example, in the PRIMUM trial (see Box 3) identifying 
because large study populations or long follow-up times 
are needed. Moreover, these outcomes are sometimes 
less appropriate: studies have shown that older people 
may prefer higher quality of life over prolonged survival 
(64 – 66). 
 Some relevant and feasible outcomes for inter -
vention studies on multimorbidity and polypharmacy 
in primary care are quality of life, quality of care, and 
medication appropriateness. Health-related quality of 
life measures (HR-QOL) are patient-related outcomes 
(PROMs), based on complex constructs that pose specifi c 
challenges to their use in older aged patients (see Box 
4). Apart from quality of life measurements, a broad vari-
ety of patient-reported outcomes are available, such as 
patient autonomy (67), and psychological well-being 
(68). An example of quality of care measurement is the 
Patient Assessment of Chronic Illness Care (PACIC) (69,70) 
that is based on the Chronic Care Model (CCM) (47). The 
development of this generic questionnaire aims at 
assessing whether the quality of care received is in line 
with the CCM and from the patient ’ s perspective. This is 
particularly essential in the case of multiple chronic con-
ditions (2,71). 
 PIL,  ‘ Polypharmacy Intervention Limburg ’ (NTR 2154): a collaborative approach of the GP, the pharmacist, and specialists to improve the 
quality of life in elderly patients through optimized chronic drug therapy in the Netherlands. 
 The nurse practitioner (NP) visits Mr Curran at his home and makes an inventory of all drugs, indications according to Mr Curran ’ s own 
knowledge, and his medication problems, such as side-eff ects and diffi  culties with adherence. The GP and the pharmacist review the 
patient ’ s medication according to the NP ’ s documentation and further electronic information. This review is checked with other medical 
specialists involved. Afterwards, the review is discussed with Mr Curran and implemented step-by-step. Mr Curran is followed-up 
for one year. 
 PRIMUM,  ‘ prioritizing multimedication in multimorbid patients ’ (ISRCTN99526053): a general practice based complex intervention to 
improve the medication appropriateness in elderly patients in Germany. 
 A healthcare assistant of the general practice assesses the medication-related problems and therapeutic preferences of Mr Curran by a 
checklist, reconciles his medication and enters drug data into a web-based drug information system. The GP optimizes the medication 
supported by computerized alerts on drug-drug interactions, inappropriate dosages, etc. in consideration of the problems identifi ed by the 
checklist. Finally, the GP discusses the adjusted medication with Mr Curran during a consultation. 
 Box 3. Interventions addressing polypharmacy. 
Recipient
Intervention received
Deliverer
Intervention 
administered
Trialist
Intervention 
monitored
Protocol
Intervention intended
feedback
data on 
adherence
data on
fidelity
 
 Figure 1. Implementation of complex interventions in trials. 
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individual needs regarding the maintenance of subjec-
tive well-being. 
 In the further development of patient-centred care 
for those with multimorbidity and polypharmacy in pri-
mary care, we should take into account the previous geri-
atric and rehabilitation experiences in this fi eld. Despite 
their research-based knowledge on multimorbidity, the 
diff erences in population in primary care, as well as the 
context (e.g. longitudinality) have to be valued. 
 One limitation of this investigation was our purpo-
sive sampling of experts. Despite the multidisciplinary 
nature of our workshop, we lacked for instance the 
patient perspective due to limitation to the number of 
participants. However, the number of group members 
was suffi  cient to render reliable composite judgements, 
and in larger groups, members might actually be reluc-
tant to express views (86,87). 
 In this paper, we presented selected studies to 
exemplify methodological choices necessary in this fi eld. 
Similarly, not all studies and developments in this fi eld 
could be discussed in depth; we limited ourselves to 
examples that were most relevant to clinical care. 
 Conclusion 
 Overall, we see that complexity is a main underlying 
theme: multimorbidity presents a complexity of condi-
medication adherence as a strong mediator could 
change the complex intervention to maximise the 
improvement in this intermediate outcome and thus 
the fi nal outcome. Future process evaluations may uti-
lize an approach similar to Baron and Kenny’s mediation 
modeling, but which explicitly allows for unmeasured 
confounding (84). 
 DISCUSSION 
 Given the high prevalence and impact of both multimor-
bidity and polypharmacy there is an urgent need for 
the development of more eff ective interventions 
based on a solid theoretical framework that take into 
account both the opportunities off ered by conditions 
with shared pathophysiology and the need for making 
patient-centred decisions for competing demands. 
 ‘ Complexity ’ seems to be the agenda of developments 
in epidemiology, clinical knowledge, research method-
ology, outcome measurement, and in studies regarding 
new approaches to health care. Complexity means that 
in multimorbidity research, environmental, psychoso-
cial and biological factors interfere with the relationship 
between intervention and outcomes, which is often not 
easily understood (85). In complex multimorbid patients 
like Mr Curran there is no simple cause-eff ect relation-
ship. In addition to healthcare needs, they have complex 
 Most measures for disease-specifi c health-related quality of life (HR-QOL) have been developed for younger populations. Particularly in 
patients with multimorbidity, quality of life may thus be systematically underestimated (72). Psychometrically-sound generic quality of life 
measures that incorporate age-specifi c quality of life dimensions have only been developed recently (e.g. WHO-QOL-OLD) (73). From a 
psychological perspective, quality of life of older people is considered a multidimensional construct that includes objective indicators and 
subjective evaluations related to developmental processes of growth, maintenance, and resiliency, as well as management of loss (74,75). 
For Mr Curran the crucial question is not only to learn about his medical conditions, but also deal with his everyday needs or to be able to 
organize his new life and his medical requirements (e.g. medication) and perceive stability or even improvement in daily life. Environmental 
Gerontology adds to this holistic perspective the insight that quality of life unfolds in terms of person-environment exchange processes, 
such as belonging and agency (76,77). Whereas processes of belonging (e.g. attitudes, attachment) are particularly linked to the 
maintenance of one ’ s integrity and identity, processes of agency (e.g. adaptation, compensation) are linked to outcomes of independence 
and autonomy (78). Both processes have to be considered for a better understanding of older patients ’ prioritization of treatment goals in 
multimorbidity, adherence to complex drug regimes in polypharmacy and the maintenance of subjective well-being in the face of multiple 
chronic health conditions. For Mr Curran that could mean to follow up some (adapted) identity-relevant familiar patterns of behaviour or to 
maintain parts of his former life, e.g. being out and about in the countryside again or doing some gardening in front of his house, which 
might help to reduce some aspects of his perceived frustration and bring some stability back into his life. 
 Box 4. HR-QOL measures in old age. 
 The perception of inappropriateness is highly variable within clinical and theoretical disciplines and often lacks solid evidence. 
Polypharmacy is often well justifi ed, and medications rated as inappropriate in older patients (e.g. amiodarone) are elsewhere part of 
established therapy guidelines or do not have an alternative. Of Mr Curran ’ s 13 medications, each is approved for at least one of his 
conditions, and doses prescribed match their label restrictions. It seems desirable, therefore, to use an integrated approach describing the 
entire prescription at diff erent levels of appropriateness. The MAI consists of 10 items on prescription quality for each prescription (e.g. 
dose, duration, indication, interactions, practicability, and costs) but also provides a quality indicator for the entire medication regimen (79). 
The MAI usually uses data from chart review (80,81), but underprescribing and eff ectiveness of the medication cannot be reliably detected 
unless the prescription history and some clinical parameters are known. For example, only if we knew the actual lactate dehydrogenase of 
Mr Curran, could we decide whether the low dose of his simvastatin prescription is ineff ective. Therefore, the accuracy of the MAI ratings 
increases with the degree of detail in the chart. Thus, the MAI is less relevant when analysing larger secondary data sources for 
appropriateness. 
 Box 5. The medication appropriateness index (MAI). 
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